Main Article Content

Abstract

Eclipta alba Linn. (Asteraceae) is traditionally claimed and reported to possess antarthritic and anti-inflammatory activity. Wedelolactone, an active constituent of Eclipta alba Linn responsible for its therapeutic effectiveness, is poorly water soluble and less bioavailable. Hence in the present study, we proposed a SNEDDS formulation of wedelolactone rich extracts of Eclipta alba Linn. (EAF) and evaluated its effect in Freund's complete adjuvant (FCA) induced arthritis in rats.EAF reduced increase in paw volume and hyperalgesia in 50, 100 and 200 mg/kg doses significantly. It restored all cytokines (Tumor Necrosis Factor-α, Interleukin-1β and Interleukin-6); hematological and biochemical parameters altered due to FCA induction. The histopathology further supported the potential of EAF in arresting the progress of the disease. It protected cartilage destruction and exudation of inflammatory cells dose dependently. In conclusion, the EAF exhibited potent antarthritic potential due to the increased bioavailability of wedelolactone and other constituents. The mechanism of action is mainly mediated through inhibition of cytokines, anti-inflammatory and antioxidant potential of wedelolactone.

Keywords

Eclipta alba wedelolactone cytokines rheumatoid arthritis

Article Details

How to Cite
Atre B N, Arulmozhi S, Sathiyanarayanan L, Dhapte-Pawar V V, & Mahadik K R. (2021). Formulation of wedelolactone enriched extract with enhanced potential to inhibit cytokines in experimental arthritis. International Journal of Research in Pharmaceutical Sciences, 12(2), 1283-1291. https://doi.org/10.26452/ijrps.v12i2.4678